Author:
Vandenplas Yannick,Simoens Steven,Van Wilder Philippe,Vulto Arnold G.,Turk Florian,Huys Isabelle
Abstract
Abstract
Background
A competitive market for off-patent biologicals leads to more affordable and high-quality healthcare. In recent years, Belgium has been characterized by its low use of biosimilars and by its shifts from off-patent biologicals toward new alternative therapies. Yet, the prescribing decisions involved in these observations are poorly understood. This study aims to better understand prescribing choices among Belgian physicians in the ambulatory care setting.
Methods
This study consisted of two phases. First, a scoping literature review to identify determinants of prescribing choices was conducted. Scientific databases (Embase and PubMed) were searched until 4 November 2021. Second, the nominal group technique (NGT) was employed during focus group discussions with Belgian physicians to consider and validate these determinants for off-patent biologicals in the Belgian context. The qualitative data resulting from the literature review and focus group discussions were analyzed using the thematic framework method.
Results
Fifty-three scientific articles that discussed elements that determine prescribing choices were identified. Out of these, 17 determinants of prescribing choices were found. These were divided into five categories: (1) product-related, (2) physicians’ personal, (3) healthcare system-related, (4) patient-related, and (5) determinants related to the pharmaceutical company or brand. Nineteen Belgian physicians from different therapeutic areas that regularly prescribe biologicals then participated in focus group discussions. Using the NGT, the group discussions revealed that prescribing choices for off-patent biologicals are determined by a complex set of elements. Clinical data, geographical region, working environment, pharmaceutical marketing, patient profile, clinical guidelines, and preference of key opinion leaders (KOL) were considered most influential. Physicians indicated that the importance of these determinants differs depending on product classes or therapeutic domain.
Conclusions
Multiple elements determine the choice of an off-patent biological or biosimilar product. The importance of each of these determinants varies depending on the context in which the prescribing choice is made. To increase the prescription of best-value biologicals in the Belgian ambulatory care, a set of synergistic measures is required including information for healthcare providers (HCP) and patients, prescribing feedback, prescribing targets, tangible incentives, KOL involvement, guidelines regarding pharmaceutical promotion, and regular revision of reimbursement modalities.
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. IQVIA. The global use of medicines 2022: outlook to 2026. 2021. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicines-2022/global-use-of-medicines-2022-outlook-to-2026-12-21-forweb.pdf. Accessed 16 Dec 2021.
2. OECD. Health spending (indicator). 2022. https://data.oecd.org/healthres/health-spending.htm#indicator-chart. Accessed 5 May 2022.
3. OECD. Pharmaceutical spending (indicator). 2022. https://data.oecd.org/healthres/pharmaceutical-spending.htm#indicator-chart. Accessed 3 May 2022.
4. National Institute for Health and Disability Insurance (NIHDI). Budget 2021 – Begrotingsvoorstel van het Verzekeringscomité. 2020. https://www.riziv.fgov.be/SiteCollectionDocuments/RIZIV_ARGV_2020_065.pdf. Accessed 16 Dec 2020.
5. IQVIA. The Impact of Biosimilar Competition in Europe. 2020. https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe. Accessed 16 Jan 2021.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献